Centrillion Technology, Inc. Company Profile

Background

Centrillion Technology, Inc., founded in 2009 and headquartered in Palo Alto, California, is a biotechnology firm specializing in DNA chip technologies. The company's mission is to empower researchers, physicians, and consumers with responsible and cost-effective access to genomic information, thereby advancing personalized healthcare, molecular diagnostics, and individualized wellness management.

Key Strategic Focus

Centrillion focuses on developing innovative DNA chips and molecular assays to facilitate large-scale genomic analyses, including DNA sequencing. Their strategic objectives include:

• Advancing DNA Chip Technology: Enhancing the capabilities of DNA chips for applications such as rapid multiplex pathogen detection, whole genome viral sequencing, human genotyping, and spatial transcriptomics.

• Product Development: Offering products like VirusHunter™ assays for fast detection and viral sequencing, whole genome genotyping assays, and spatial transcriptomics tools.

• Market Expansion: Extending their reach into international markets, as evidenced by the expansion of offices in Hsinchu, Taiwan.

Financials and Funding

Centrillion has secured multiple funding rounds since its inception:

• Seed Round (October 2009): Raised $5.8 million.

• Series A (July 2010): Secured $2 million.

• Series B (April 2013): Amount undisclosed.

• Series C (March 2015): Amount undisclosed.

• Series D (September 2016): Amount undisclosed.

• Later Stage VC (July 2018): Amount undisclosed.

• Secondary Transaction (May 2022): Amount undisclosed.

The company has attracted notable investors, including ARM, WeDoctor, Zfounder, GRC SinoGreen Fund, and The National Human Genome Research Institute.

Pipeline Development

Centrillion's product pipeline includes:

• VirusHunter™ QuadCore Chips: Designed for SARS-CoV-2 whole genome sequencing and multi-pathogen detection.

• Whole Genome Genotyping Assays: Utilizing ligation and extension-based methods for high-quality human genotyping results.

• Spatial Transcriptomics Tools: Offering micron-scale resolution for quantitative detection of thousands of RNA targets with spatial resolution.

Technological Platform and Innovation

Centrillion's technological innovations encompass:

• In Situ Synthesized DNA Chips: Capable of producing billions of different DNA sensors on a single wafer, enabling applications like rapid multiplex pathogen detection and spatial transcriptomics.

• VirusHunter™ Assays: Utilizing advanced chemistry and manufacturing techniques for fast detection and viral sequencing.

• High-Throughput Virus Detection: Employing ATOM™ chips for detecting sequences of multiple pathogens, antibiotic resistance genes, and controls.

Leadership Team

• Wei Zhou, Ph.D.: Co-Founder, Chief Executive Officer, President, and Chairman.

• James Zhang, Ph.D.: Chief Strategy Officer.

• Glenn McGall, Ph.D.: Co-Founder and Senior Vice President of Technology.

• Jeremy Edwards, Ph.D.: Vice President of Sequencing Technology.

• Feng Li, Ph.D.: President and Chairman.

Leadership Changes

In May 2015, Centrillion expanded its executive team by appointing a new Chief Strategy Officer.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in genomic technologies, is experiencing significant growth due to advancements in personalized medicine and molecular diagnostics. Centrillion operates in a competitive landscape with several key players.

Competitor Analysis

• Genomic Health: Focuses on genomic-based diagnostic tests for cancer.

• QIAGEN: Provides sample and assay technologies for molecular diagnostics.

• MOgene: Offers genomic services and products.

• Agilent Technologies: Supplies instruments and tools for laboratories.

• DNA Genotek: Specializes in biological sample collection products.

• PerkinElmer, Inc.: Provides products and services for diagnostics and life sciences.

Strategic Collaborations and Partnerships

Centrillion has engaged in strategic collaborations to enhance its market position and innovation capacity:

• WeDoctor Partnership (July 2018): Aimed at expanding services and technological capabilities.

• ARM IoT Fund Investment (July 2018): Supported the expansion of manufacturing capabilities in Hsinchu, Taiwan.

Operational Insights

Centrillion's strategic considerations include:

• Market Positioning: Differentiating through cost-effective genomic access and personalized healthcare solutions.

• Competitive Advantages: Leveraging proprietary DNA chip technologies and a focus on innovation to maintain a competitive edge.

Strategic Opportunities and Future Directions

Centrillion's future directions involve:

• Product Diversification: Expanding the range of genomic tools and services.

• Global Expansion: Strengthening international presence, particularly in Asia.

• Technological Innovation: Continuing to advance DNA chip technologies to meet evolving market needs.

Contact Information

• Website: www.centrilliontech.com